Patients with extensive-stage small cell lung cancer (ES-SCLC) have a 10-month survival of 10 months following standard frontline chemotherapy. Join the experts in discussing immune checkpoint inhibitors (ICIs) in patients with SCLC.
Credit available for this activity expires: 6/15/2023
Earn Credit / Learning Objectives & Disclosures: [ Ссылка ]
![](https://s2.save4k.ru/pic/F3sg4PMMoZs/maxresdefault.jpg)